Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
D Patoulias, M Doumas, C Papadopoulos… - Clinical …, 2021 - Springer
Abstract Coronavirus disease-2019 (COVID-19) represents a global public health
nightmare. The “cytokine storm,” the most prominent underlying pathophysiologic …
nightmare. The “cytokine storm,” the most prominent underlying pathophysiologic …
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
F Solimani, K Meier, K Ghoreschi - European journal of …, 2021 - Wiley Online Library
Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects
of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial …
of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial …
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
Abstract Purpose The Coronavirus disease 2019 (COVID-19) pandemic is one of the most
devastating global problems. Regarding the lack of disease-specific treatments, repurposing …
devastating global problems. Regarding the lack of disease-specific treatments, repurposing …
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19
X Zhang, Y Zhang, W Qiao, J Zhang, Z Qi - International …, 2020 - Elsevier
In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly …
respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly …
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
FR Spinelli, F Conti, M Gadina - Science immunology, 2020 - science.org
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19 |
Science Immunology news careers commentary Journals Science Science brought to you …
Science Immunology news careers commentary Journals Science Science brought to you …
[引用][C] Baricitinib-a januase kinase inhibitor-not an ideal option for management of covid 19
[HTML][HTML] JAK inhibitors and COVID-19
G Levy, P Guglielmelli, P Langmuir… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Abstract During SARS-CoV-2 infection, the innate immune response can be inhibited or
delayed, and the subsequent persistent viral replication can induce emergency signals that …
delayed, and the subsequent persistent viral replication can induce emergency signals that …
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling
BK Gajjela, MM Zhou - Drug discovery today, 2022 - Elsevier
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused the unprecedented COVID-19 pandemic, which has infected over 178 million people …
caused the unprecedented COVID-19 pandemic, which has infected over 178 million people …
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
O Melikhov, T Kruglova, K Lytkina… - Annals of the …, 2021 - ard.bmj.com
Janus kinase (JAK) inhibitors for the treatment of hospitalised patients with COVID-19 have
been extensively studied. Initially, at the start of the pandemic outside of China, baricitinib …
been extensively studied. Initially, at the start of the pandemic outside of China, baricitinib …
Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID‐19
SCJ Jorgensen, CLY Tse, L Burry… - … : The Journal of …, 2020 - Wiley Online Library
A hyperinflammatory response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …